Arturo Molina Md sold $1.1M of PTGX
Chief Medical Officer at Protagonist Therapeutics, Inc. 20,000 shares at an average of $56.27, traded Jun 9, 2025, filed Jun 11, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 21% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.2%, 3m +4.3%, 6m +65.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-058597, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 9, 2025 | MOption exercise Common Stock | +10,000 | $8.04 | $80k | 93,892 | Jun 11, 2025 |
| Jun 9, 2025 | SOpen-market sale Common Stock | -10,000 | $55.51 | $555k | 83,892 | Jun 11, 2025 |
| Jun 10, 2025 | MOption exercise Common Stock | +10,000 | $8.04 | $80k | 93,892 | Jun 11, 2025 |
| Jun 10, 2025 | SOpen-market sale Common Stock | -10,000 | $57.03 | $570k | 83,892 | Jun 11, 2025 |
| Jun 9, 2025 | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 85,971 | Jun 11, 2025 |
| Jun 10, 2025 | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 75,971 | Jun 11, 2025 |
Related signals
Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $8.3M 58,629 shares | -50% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $18M 125,000 shares | -22% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $15M 100,000 shares | -17% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $1.1M 9,000 shares | -53% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $969k 9,000 shares | -53% | |
| 24Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $897k 9,000 shares | -53% | |
| 28Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $7.5M 75,000 shares | -13% | |
| 48Moderate | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $7.5M 75,000 shares | -13% | |
| 53Moderate | Protagonist Therapeutics, Inc | Bryan Giraudo director | $5.9M 59,130 shares | -93% | |
| 34Weak | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $185k 1,750 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.